Quinazolin‐4(3 H )‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications
Archiv der Pharmazie · 2025-06 · 358 (6)
DOI: 10.1002/ardp.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 26.06.2025. Verfasst von Feyzi Sinan Tokalı und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Türkiye. Hauptthemen laut MEDLINE: Aldehyde Reductase, Glycoside Hydrolase Inhibitors, alpha-Glucosidases, Quinazolinones. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: This study was supported by the Scientific Research Projects Coordinatorship of Kafkas University with project number 2023-FM-65..
Themen: Diabetes mellitus
Abstract (Originalsprache)
A series of novel glitazones containing thiazolidine‐2,4‐dione and quinazolin‐4(3 H )‐one moieties were synthesized to explore their potential as dual inhibitors of aldose reductase (ALR2) and α‐glucosidase (α‐Glu), two key enzymes involved in diabetes and its complications. In vitro assays revealed that compounds 8 (cyclohexyl substituted), 9 (phenethyl substituted), and 11 (phenyl substituted) exhibited potent inhibitory effects on both enzymes, with 11 being the most active, showing an ALR2 inhibition ( K i = 0.106 µM) approximately nine times more effective than the standard epalrestat (EPR) ( K i = 0.967 µM) and α‐Glu inhibition ( K i = 0.648 µM) about six times stronger than acarbose (ACR) ( K i = 0.3.775 µM). Molecular docking and molecular dynamics simulations showed that compound 11 formed strong interactions with residues Trp‐20, Gln‐183, and Asp‐43 for ALR2 and residues Arg‐200, Arg‐400, and Glu‐271 for Phe‐297. Cytotoxicity assays performed on healthy cell lines (HUVEC and BEAS‐B2) revealed that the tested compounds were nontoxic at inhibitory concentrations. These findings highlight the potential of compound 11 as a promising dual inhibitor for managing diabetes and its complications, providing a foundation for further optimization and therapeutic exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Türkiye.
- Department of Pharmacy Services, Nihat Delibalta Göle Vocational High School, Ardahan University, Ardahan, Türkiye.
- Department of Chemistry, Faculty of Science, Atatürk University, Erzurum, Türkiye.
- Department of Biotechnology, Institute of Health Sciences, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.
- Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.
- Department of Veterinary Physiology, Faculty of Veterinary Medicine, Kafkas University, Kars, Türkiye.
ORCID-Profile: Feyzi Sinan Tokalı, Yeliz Demir, Halil Şenol
Förderung
- This study was supported by the Scientific Research Projects Coordinatorship of Kafkas University with project number 2023-FM-65.
Zitieren
APA
Tokalı, F. S., Demir, Y., Ateşoğlu, Ş., Tokalı, P., & Şenol, H. (2025). Quinazolin‐4(3 H )‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications. Archiv der Pharmazie, 358(6). https://doi.org/10.1002/ardp.70033
Vancouver
Tokalı FS, Demir Y, Ateşoğlu Ş, Tokalı P, Şenol H. Quinazolin‐4(3 H )‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications. Archiv der Pharmazie. 2025;358(6). doi:10.1002/ardp.70033
BibTeX
@article{Tokal2025,
author = {Tokalı, Feyzi Sinan and Demir, Yeliz and Ateşoğlu, Şeyma and Tokalı, Pelin and Şenol, Halil},
title = {Quinazolin‐4(3 H )‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {6},
doi = {10.1002/ardp.70033}
}
EUVIMED